PAHC

The headline GAAP P/E of 26.7 is misleading. FY2025 net income of $48.3M (+1898%) is lapping a collapsed FY2024 base of just $2.4M, which the MD&A shows was crushed by $19.4M of after-tax FX losses, pension settlement and acquisition costs. The cleaner read is the company's own reconciliation: adjusted net income of $84.9M (+76%) and adjusted diluted EPS of $2.09 (up from $1.19). At $31.81 that is roughly 15x adjusted earnings for a business that just grew revenue 27.4% to $1.30B — an undemanding multiple if the run-rate holds.

The growth is real but bought: the MD&A's repeated references to 'the Acquisition' (the Zoetis medicated-feed-additives/genetics portfolio) explain the +27% revenue, the $288.7M investing outflow and the $207.1M of new financing. That is the central tension. Revenue has compounded steadily for five years ($833M→$1.30B) and ROE is a healthy 16.9%, but the deal levered the balance sheet to 3.76x liabilities/equity against only $68M of cash. Operating cash flow of $80.1M comfortably covers $38.3M capex and the $19.4M dividend, so the leverage is serviceable — but it removes the margin for error. Margins are structurally thin (30.9% gross, 8.5% operating, 3.7% net), consistent with a feed-additive/nutrition business rather than branded pharma, so the equity story is volume, synergy capture and deleveraging, not margin expansion.